Intuitive Surgical, Inc.
General ticker "ISRG" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $184.9B (TTM average)
Intuitive Surgical, Inc. follows the US Stock Market performance with the rate: 26.2%.
Estimated limits based on current volatility of 0.8%: low 566.75$, high 575.35$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 15638 (+14.3%) as of 2024
- US accounted for 43.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Litigation risks, Liquidity and credit risks, Supply chain disruptions, Manufacturing delays and scale, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [451.39$, 591.64$]
- 2025-12-31 to 2026-12-31 estimated range: [477.97$, 628.37$]
Financial Metrics affecting the ISRG estimates:
- Negative: with PPE of 72.2 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 28.12 > 18.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.09 > 6.04
- Positive: -4.48 < Investing cash flow per share per price, % of -1.74
- Positive: -8.75 < Industry operating profit margin (median), % of -7.19
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 0.33 < Operating cash flow per share per price, % of 1.29
Short-term ISRG quotes
Long-term ISRG plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $6,222.20MM | $7,124.10MM | $8,352.10MM |
| Operating Expenses | $4,645.10MM | $5,357.30MM | $6,003.20MM |
| Operating Income | $1,577.10MM | $1,766.80MM | $2,348.90MM |
| Non-Operating Income | $29.70MM | $192.10MM | $324.90MM |
| R&D Expense | $879.00MM | $998.80MM | $1,145.30MM |
| Income(Loss) | $1,606.80MM | $1,958.90MM | $2,673.80MM |
| Taxes | $262.40MM | $141.60MM | $336.30MM |
| Profit(Loss)* | $1,322.30MM | $1,798.00MM | $2,322.60MM |
| Stockholders Equity | $11,041.90MM | $13,307.60MM | $16,433.70MM |
| Inventory | $893.20MM | $1,220.60MM | $1,487.20MM |
| Assets | $12,974.00MM | $15,441.50MM | $18,743.20MM |
| Operating Cash Flow | $1,490.80MM | $1,813.80MM | $2,415.00MM |
| Capital expenditure | $532.40MM | $1,064.20MM | $1,111.20MM |
| Investing Cash Flow | $1,370.80MM | $-360.10MM | $-3,272.80MM |
| Financing Cash Flow | $-2,572.30MM | $-287.60MM | $150.90MM |
| Earnings Per Share** | $3.72 | $5.12 | $6.54 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.